IRMD Stock Recent News
IRMD LATEST HEADLINES
IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.
LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005.
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.